SS&C upgraded to Buy from Hold at Jefferies

Jefferies upgraded SS&C to Buy from Hold with a price target of $94, up from $70, as part of a Q4 preview. After many years of investment, the company has reached a point where it is capable of sustaining mid-single-digit organic growth, and is on a path back to 40% adjusted EBITDA margins, the analyst tells investors in a research note. The firm says that with capital markets activity improving, it sees upside to Intralinks, a product refresh cycle benefiting Blue Prism, and potential new customer wins validating SS&C’s investment in DomaniRx. Jefferies cites expectations of a return to sustainable mid-single-digit organic revenue growth for the upgrade of SS&C.